Cancer Management and Research (Feb 2019)
Meta-analysis of the prognostic role of HE4 expression in cancer patients: clinical insights into interpretation of clinical outcomes
Abstract
Rama Jayaraj,1 Chellan Kumarasamy2 1College of Health and Human Sciences, Charles Darwin University, Casuarina, NT, Australia; 2University of Adelaide, North Terrace Campus, Adelaide, SA, AustraliaAn article titled, “Prognostic values of HE4 expression in patients with cancer: a metaanalysis”, was recently published in the journal, Cancer Management and Research, detailing a study conducted by Dai et al.1 This study aims to validate and estimate the effectiveness of HE4 as a prognostic marker in cancer. We commend the authors for the study’s focus on all types of cancers, as well as the associated subgroup analysis detailing the results for individual cancer types and population groups. This study is valuable as a guidepost for informing future research on HE4 as a prognostic biomarker to predict the cancer patients’ clinical outcomes. However, there are a few points that require to be addressed regarding the study conducted.Authors’ replyCong Dai,1 Yi Zheng,1 Tian Tian,1 Zhijun Dai,1 Jun Lyu2 1Department of Oncology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710004, China; 2Jun Lyu, Clinical Research Center, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, ChinaWe thank Dr Rama Jayaraj and Chellan Kumarasamy for their interest and comments. They came up with several valuable points that improved our meta-analysis.1Read the original paper.
